Nurix Therapeutics Inc [NRIX] stock prices are down -10.13% to $9.76 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The NRIX shares have gain 4.05% over the last week, with a monthly amount glided 6.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on March 17, 2025, when Leerink Partners initiated its Market Perform rating and assigned the stock a price target of $16. Previously, BTIG Research started tracking the stock with Buy rating on December 10, 2024, and set its price target to $35. On December 06, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $35 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $35 on October 24, 2024. Jefferies initiated its recommendation with a Buy and recommended $41 as its price target on October 11, 2024. In a note dated July 31, 2024, Truist initiated a Buy rating and provided a target price of $36 on this stock.
The stock price of Nurix Therapeutics Inc [NRIX] has been fluctuating between $8.18 and $29.56 over the past year. Currently, Wall Street analysts expect the stock to reach $27.25 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $9.76 at the most recent close of the market. An investor can expect a potential return of 179.2% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
The Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 83.69M for trailing twelve months, representing a drop of -37.29%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -3.19%, Pretax Profit Margin comes in at -2.92%, and Net Profit Margin reading is -2.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.54 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Nurix Therapeutics Inc [NASDAQ:NRIX]’s Current Ratio is 5.35. On the other hand, the Quick Ratio is 5.35, and the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 8.97, the price to book ratio is 2.02.
Transactions by insiders
Recent insider trading involved van Houte Hans, Chief Financial Officer, that happened on Aug 01 ’25 when 5402.0 shares were sold. Officer, JOHANNES VAN HOUTE completed a deal on Aug 01 ’25 to buy 5402.0 shares. Meanwhile, Chief Financial Officer van Houte Hans sold 4304.0 shares on Jul 30 ’25.
